The present invention provides an immunomodulatory composition useful for treating or preventing joint damage comprising at least a set of peptides possessing an amino acid sequence having at least 80%, 85% and 90% sequence identity with the peptides corresponding to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 and a method for the treatment or prevention of joint damage comprising the steps of a) extract monocytes from a patient with a rheumatological disease; b) culture the monocytes extracted in the previous step in AIM-V medium with GM-CSF and IL-4; c) wash the monocytes and add dexamethasone; d) load the tDCs with the immunomodulatory composition comprising autoantigenic peptides; e) add MPLA; and f) incorporate the tDCs loaded with autoantigenic peptides into the patient. The present invention includes methods for the treatment or prevention of rheumatological disease comprising a wide range of tDCs performed by different protocols.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

The present invention relates to anti-polyomavirus antibodies, antibody fragments, and their uses for the prevention and treatment of BK or JC virus infection and associated diseases.

The present invention relates to anti-polyomavirus antibodies, antibody fragments, and their uses for the prevention and treatment of BK or JC virus infection and associated diseases.

The present invention comprises an apparatus and method for producing a microparticle and pharmaceutical compositions thereof. The apparatus and method rely on continuous inkjet (CIJ) printing to provide high quality microparticles at an improved rate.

The present invention comprises an apparatus and method for producing a microparticle and pharmaceutical compositions thereof. The apparatus and method rely on continuous inkjet (CIJ) printing to provide high quality microparticles at an improved rate.

by screening using a high-throughput evaluation system relating to the promotion of the extracellular secretion of trimers of the causative proteins COL4A3/A4/A5, which decreased in the renal tissue of patients with Alport syndrome (AS), it was found that cyclosporin A has an effect of promoting extracellular secretion of trimers of type-IV collagen. From further studies, it was found that Alisporivir and NIM258, which do not inhibit calcineurin, also have an action to promote extracellular secretion of type-IV collagen. Furthermore, the present inventors have found that these actions are based on the cyclophilin D inhibitory mechanism, and have found a radical therapeutic agent for AS by inhibition of cyclophilin D. The present invention provides a composition and an AS therapeutic/prophylactic drug, which contain a cyclophilin D inhibitor as an active ingredient, for promoting the secretion of collagen trimers in cells having a mutated type-IV collagen gene.